To include your compound in the COVID-19 Resource Center, submit it here.

Mapping metastases

Memorial Sloan-Kettering Cancer Center, Cornell University and Hybrid Silica Technologies Inc. have developed a silica nanoparticle-based imaging agent that detects micrometastases in the lymph nodes of two animal models of melanoma.1 The nanoparticles can be used for both PET and fluorescence imaging, and the researchers believe it could help noninvasively detect lymph node metastases prior to surgery and, along with handheld devices, guide tumor resection during surgery.

In January, the investigators started a Phase 0 microdosing trial of the nanoparticles in metastatic melanoma patients. The researchers are also forming a new company, Clinical Silica Technologies Inc., to pursue diagnostic and therapeutic applications of the nanoparticle platform.

Michelle Bradbury, who led the team that developed the technology, is the principal investigator for the trial, which will use PET scans to look at pharmacokinetics, safety and

Read the full 1322 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers